Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights
• By Emily Hayes
Phase III data for J&J's Darzalex in frontline multiple myeloma will be a highlight of a late-breaker session at the ASH meeting. Above, 3D rendering of the CD38 (ectodomain fragment) enzyme, the target of Darzalex.
